Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis.

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Neuroinflammation exacerbates ALS progression, but its triggers are not fully understood.

Purpose of the Study:

• To investigate the role of mutant superoxide dismutase 1 (SOD1) in initiating neuroinflammation in ALS.
• To explore IL-1beta as a potential therapeutic target in ALS.

Main Methods:

• Utilized G93A-SOD1 transgenic mouse models of ALS.
• Assessed caspase-1 activation, IL-1beta production, and inflammasome activity in microglia.
• Investigated the impact of caspase-1 or IL-1beta deficiency and IL-1 receptor antagonist (IL-1RA) treatment on disease progression and lifespan.

Main Results:

• ALS-linked mutant SOD1 triggers caspase-1 and IL-1beta release from microglia.
• Mutant SOD1-induced IL-1beta production is linked to amyloid-like misfolding and independent of SOD1 enzymatic activity.
• Autophagy antagonizes mutant SOD1-driven inflammasome activation.
• Inhibition of caspase-1, IL-1beta, or IL-1 signaling prolonged lifespan and reduced neuroinflammation in SOD1 transgenic mice.

Conclusions:

• Microglial IL-1beta is a key mediator of neuroinflammation in ALS.
• Targeting the IL-1 pathway offers a promising therapeutic strategy for ALS treatment.